In this context, systematic administration of Plk1 inhibitors could reduce dramatically ASCs viability and impair their functionality by inducing apoptosis and altering their biological features like anti-inflammation, which are pivotal for the fate of tumor cells. This evidence concerns the gene PLK1 and neoplasm.